ArticleJournal of internal medicine2025
Trends, timing, and predictors of alcohol use disorder treatment among US adult cancer survivors.
Article in Journal of internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Trends, timing, and predictors of alcohol use disorder treatment among US adult cancer survivors.Journal of internal medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundLittle is known about the initiation of alcohol use disorder (AUD) treatments among cancer survivors, despite the unique harms that unhealthy alcohol use may have on this population. We assessed patterns, timing, and predictors of AUD treatment among cancer survivors.
methodsWe used commercial claims data on US adult cancer survivors from 2011 to 2021 in this retrospective cohort study. We included individuals with a new AUD diagnosis and continuous insurance enrollment. We measured initiation and timing of Food and Drug Administration (FDA)-approved (naltrexone, acamprosate, and disulfiram), non-FDA-approved (gabapentin, topiramate, and baclofen), and investigational (ondansetron and varenicline) medications for AUD (MAUDs), psychosocial therapies, and rehabilitation for AUD. We employed survival analysis to identify sociodemographic and clinical predictors of time to AUD treatment initiation.
resultsAmong 6,682,292 cancer survivors, 44,081 individuals newly diagnosed with AUD met the inclusion criteria. Of these, 14.7% initiated FDA-approved MAUDs (3.0%), psychosocial therapy (13.0%), or both (1.3%). The median time to initiate FDA-approved MAUD or psychosocial therapy was 28 days. Overall, 6.3% and 10.4% of cancer survivors, respectively, initiated non-FDA-approved and investigational MAUDs. Age, use of antineoplastic agents, mental disorders, and comorbidity severity are potential determinants with varying effects on AUD treatment initiation.
conclusionLess than 15% of cancer survivors initiated recommended MAUDs or psychosocial therapy in the year following their new AUD diagnoses, and those who did initiate treatment did so nearly a month after receiving AUD diagnoses. Interventions are warranted to enhance treatment initiation among cancer survivors with AUD to reduce alcohol-related harms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.